Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Interest ReceivablesChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Net Cash Flow: 2024-2025

  • Abivax's Net Cash Flow fell 123.19% to -$47.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$123.5 million, marking a year-over-year change of. This contributed to the annual value of -$117.7 million for FY2024, which is 147.53% down from last year.
  • As of Q2 2025, Abivax's Net Cash Flow stood at -$47.5 million, which was down 12.68% from -$42.1 million recorded in Q1 2025.
  • In the past 5 years, Abivax's Net Cash Flow registered a high of -$12.7 million during Q1 2024, and its lowest value of -$47.5 million during Q2 2025.
  • Its 2-year average for Net Cash Flow is -$30.9 million, with a median of -$31.7 million in 2024.
  • Data for Abivax's Net Cash Flow shows a maximum YoY slumped of 232.67% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Abivax's Net Cash Flow stood at -$21.3 million in 2024, then tumbled by 123.19% to -$47.5 million in 2025.
  • Its last three reported values are -$47.5 million in Q2 2025, -$42.1 million for Q1 2025, and -$21.3 million during Q2 2024.